title: A retrospective study of plasma cell infiltrates in explanted renal allografts.
abstract: Renal transplantation is the most effective therapy in end-stage renal disease. The prognosis for transplant survival is still determined by rejection. When plasma cells predominate in the cellular infiltrate of allografts in rejection, it is called plasma cell-rich rejection, which has a poor prognosis. To study the correlation between plasma cell infiltration and humoral rejection, and to explore whether the local plasma cells were involved in renal allograft loss we analyzed 40 explanted grafts and 20 specimens removed for other diseases. All specimens were embedded, deparaffined, and stained with hematoxylin eosin (HE) for analysis by immunohistochemistry (IH). Renal allograft rejection was classified according to the Banff 1997 criteria with examinations for C4d deposition and CD138 expression. Positive C4d staining was defined by linear endothelial C4d deposition in > or =25% of cortical peritubular capillaries. The specimens designated as CD138-positive demonstrated strong and diffuse staining characteristics; trace or rare CD138-positive were classified as negative. Our results showed that among 40 renal graft specimens, 17 cases were C4d-positive, 23 cases were CD138-positive, and 13 cases were C4d and CD138 double-positive, namely, 42.5%, 57.5%, and 32.5%, respectively. Among the double-positive cases, there were 2 patients with a diagnosis of acute cellular rejection, 1 with hyperacute rejection, and 10 with chronic humoral rejection. C4d deposition and CD138-positive plasma cell infiltrate were related by a Spearman analysis (r = 0.330; P = .038). In the control group, there was only 1 case showing C4d positive activities. These observations suggested that infiltrated plasma cells in the renal allograft probably participate in humoral rejection through local secretion of antibodies.
authors.affiliation: Transplantation Center, the Second Affiliated Hospital, Chinese PLA General Hospital, Beijing, China.
authors.forename: X
authors.initials: X
authors.lastname: Xu
authors.forename: B
authors.initials: B
authors.lastname: Shi
authors.forename: M
authors.initials: M
authors.lastname: Cai
authors.forename: Y
authors.initials: Y
authors.lastname: Han
authors.forename: Q
authors.initials: Q
authors.lastname: Wang
authors.forename: L
authors.initials: L
authors.lastname: Xu
authors.forename: L
authors.initials: L
authors.lastname: Xiao
authors.forename: W
authors.initials: W
authors.lastname: Zhou
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D015704:CD4 Antigens / Q000032:analysis; D002196:Capillaries / Q000473:pathology; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D010950:Plasma Cells / Q000473:pathology*; D011379:Prognosis; D012079:Renal Circulation; D006435:Renal Dialysis; D012086:Reoperation; D012189:Retrospective Studies; D053668:Syndecan-1 / Q000032:analysis
chemical_list: D015703:Antigens, CD; D015704:CD4 Antigens; D053668:Syndecan-1